Human Genome Sciences is one of several developers working on a new advance for lupus. This Wall Street Journal piece looks at the pipeline for lupus, which includes programs at Bristol-Myers Squibb, Genentech and Biogen Idec. There hasn't been a new therapy approved for lupus in 50 years, but these new drugs--which include Orencia and Rituxan--are being tested as treatments for the disease rather than just the symptoms.
- read the The Wall Street Journal article on lupus